Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

homa (CTCL) trial update and chronic lymphocytic leukemia (CLL) trial initiation

The forodesine HCl CTCL pivotal trial is enrolling as planned. This trial has been reviewed under a Special Protocol Assessment (SPA) from the United States Food & Drug Administration (FDA) to support regulatory approval.

BioCryst has also initiated a second clinical trial for patients with CLL based upon data presented at the December 2007 ASH meeting, which demonstrated the potential of forodesine HCl as a treatment for CLL, both as a single agent and in combination with bendamustine. This second CLL trial is a single-arm study evaluating single agent forodesine HCl as a treatment for patients with CLL; response rate is the primary endpoint. The first patient was dosed during the first quarter 2008, and BioCryst will provide a trial update by year end.

Intramuscular (i.m.) peramivir clinical development update

BioCryst initiated a Phase III i.m. peramivir trial early this year and voluntarily discontinued it after 82 of the planned 600 patients had enrolled because of a decision to pursue higher doses in a Phase II setting. Patients with influenza A and B were treated with either placebo or 300mg of i.m. peramivir. Although only 14% of the planned patients were enrolled in the study, results supported the activity of 300mg peramivir. The study was designed to show a difference within the influenza A subgroup, where preliminary clinical data showed a 30 hour reduction in time to alleviation of symptoms in patients that received peramivir compared to those who received placebo. Preliminary results from the overall population showed a reduction in time to alleviation of symptoms of approximately 14 hours. Because the trial was not carried out to completion, the sample size was small; the observed treatment effect was not statistically significant.

These results are consistent with data from previous clinical trials:

-- Reductions in time to
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 Mathematic ... at Harvard University , and funded by the ... aggressive cells within tumors can be visually identified for elimination. ... tumor,s growth. The study, which shows a topological map of ... needed time in cancer research, for while tumor cells can ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
(Date:8/21/2014)... Chester, NJ (PRWEB) August 21, 2014 ... of personal selling optimization technology and services for ... publication of “Grading Pharma’s Use of New Commercial ... of Measurement & Analytics. , The article examines ... marketing yield that are being tested in the ...
(Date:8/21/2014)... 21, 2014 Gallus BioPharmaceuticals ... development and manufacturing organization (CMO) announced today that ... an oncology company focused on the development of ... manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal ... Under the agreement the antibody will be ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Second Quarter and Six-Month Results -- NEW YORK, Aug. 19 /PRNewswire-Asia/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... and CAMBRIDGE, Massachusetts, August 19, 2010, ... ... var shortURL ... by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... an improved coating technique that could strengthen the connection ... The stronger connection -- created by manipulating signals the ... allow the implants to last longer. Implants coated ... mimics the body,s own cell-adhesion material fibronectin made 50 ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 2Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 3Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 4Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 5Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 6Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 2Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 3
(Date:8/21/2014)... BATON ROUGE In a finding that has implications ... and planets elsewhere in the solar system, LSU Associate ... funded by the National Science Foundation, or NSF, this ... sediments of a lake that lies 800 meters (2600 ... sheet support "viable microbial ecosystems.", Given that more than ...
(Date:8/21/2014)... in the journal Carcinogenesis by researchers at ... the protein adenomatous polyposis coli (APC) in suppressing colorectal ... the U.S. , Lead author Kristi Neufeld, associate professor ... the Cancer Biology program at the KU Cancer Center, ... to understand the various activities of APC, a protein ...
(Date:8/21/2014)... have developed a novel and versatile modeling strategy to ... new materials as well as for studying polyelectrolytes, including ... to model much larger and more complex polyelectrolyte systems, ... Li, lead author of a paper on the work ... Materials Science and Engineering. "This is a big step ...
Breaking Biology News(10 mins):800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... for superconductivity to branch out and meet some of ... according to a topical review `Superconductivity and the environment: ... journal Superconductor Science and Technology , which explains ... hospitals and address wider issues such as water purification, ...
... and Keshan disease (KD) are major endemic diseases in ... of Professor Xiong Guo from the Institute of Endemic ... of Xi,an Jiaotong University, Key Laboratory of Environment and ... of Trace Elements and Endemic Diseases of Health Ministry, ...
... to buy eco-friendly bamboo apparel are attracted if the ... novelty of the product, according to a new study ... many as friendly to the environment, although the Federal ... some pollutants are released in production from bamboo stalks., ...
Cached Biology News:Superconductivity to meet humanity's greatest challenges 2Superconductivity to meet humanity's greatest challenges 3Several common differentially expressed genes between Kashin-Beck disease and Keshan disease 2Several common differentially expressed genes between Kashin-Beck disease and Keshan disease 3Novelty of eco-friendly bamboo garments lures consumers -- if the price is right, Baylor study shows 2